In a study from Glasgow et al., a statistically significant difference between LAM and healthy controls for VEGF-D serum level was maintained only for LAM patients with lymphatic involvement (lymphangioleiomyomas and/or lymphadenopathy) but not for those patients with a disease restricted to the lungs (12). This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.